|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Hydralazine#Warnings]] |
| {{Hydralazine}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==Warnings==
| |
| | |
| In a few patients, hydralazine may produce a clinical picture simulating [[systemic lupus erythematosus]] including [[glomerulonephritis]]. In such patients, hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary (see [[Hydralazine injection precautions|PRECAUTIONS, Laboratory Tests]]).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIUS KABI USA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3797028-c625-4f70-ae69-8a5f6f23f1b8 | publisher = | date = | accessdate = 10 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |